Johannes Gamba

Investment Banking

Johannes has recently joined Bryan Garnier as Director in the Technology investment banking team.

Prior to joining, he worked in investment banking at Bank of America, Evercore and Morgan Stanley in both Frankfurt and London. Johannes has more than 13 years of experience in advising clients on M&A and capital markets transactions, as well as corporate defence strategies.

Abhijit Kunte

Investment Banking

Abhijit joined Bryan, Garnier & Co in 2021.

Previously, Abhijit worked as an AVP at Technology Holdings and as a Manager in corporate development at Tech Mahindra Limited.

Abhijit has completed various transactions including the sale of Nielsen+Partners to Larsen and Toubro Infotech and acquisition of Pininfarina S.p.A. by Tech Mahindra.

Abhijit holds an MBA from the Bond University in Australia and is a CPA (USA).

Kanak Sharma

Investment Banking

Kanak joined Bryan, Garnier & Co in October 2021 as Associate in the Technology team.

She has gained experience as an M&A Banker at IEG-Investment Banking Group and as a consumer tech investor at Nucom (Joint company of General Atlantic & ProSiebenSat.1). During her career, she has developed a knowledge of various sectors including Fintech, Clean Tech, B2B logistics, Proptech/ Real estate tech & E-commerce.

She holds a bachelor’s degree in economics & Statistics.

With more than 60 private and public capital-raising and M&A transactions closed in 2020, Bryan, Garnier & Co benefits from longstanding leadership in the healthcare, technology, business services and environmental sectors in Europe. Over the past 36 months, Bryan, Garnier & Co has led more than 40 ECM transactions across nine countries, raising over EUR 2.5bn. Recent successes include the IPOs and/or follow-ons for HDF Energy (Euronext Paris), Mister SPEX (Deutsche Boerse), Carbios (Euronext Paris), Azelio (NASDAQ Stockholm), McPhy Energy (Euronext Paris), Linas Matkase (NASDAQ Stockholm), Heidelberg Pharma (Deutsche Börse), Swedish Stirling (NASDAQ Stockholm), Basilea (SIX) GenSight (Euronext Paris), and Valneva (NASDAQ / Euronext Paris).

Additional recent transactions include the acquisition of DL Software by TA Associates, the sale of smartTrade to leading software private equity investor Hg Capital, the take-private of ITSM player Easyvista by Eurazeo, capital for circular economy player asgoodasnew, the sale of Specim to Konica Minolta and the sale of BlueBee to Illumina. Over the years, Bryan, Garnier & Co has distinguished itself by backing some of the most disruptive companies in the domain of alternative proteins (Prolupin), green hydrogen (McPhy Energy), cannabis (Canopy Growth), 3D printing (Materialise), blockchain and cryptocurrencies (Bitfury Group), and mRNA biotech (Moderna and BioNTech).

About Bryan, Garnier & Co

Bryan, Garnier & Co is a European, full-service growth-focused independent investment banking partnership founded in 1996. The firm provides equity research, sales and trading, private and public capital raising as well as M&A services to growth companies and their investors. It focuses on key growth sectors of the economy including Technology, Healthcare, Consumer and Business Services. Bryan, Garnier & Co is a fully registered broker dealer authorized and regulated by the FCA in the UK, the AMF in Europe and the FINRA in the U.S. Bryan, Garnier & Co is headquartered in London, with additional offices in Paris, Munich, Stockholm, Oslo, Reykjavik and New York.

(www.bryangarnier.com)